论文部分内容阅读
目的 观察培高利特作为复方左旋多巴制剂的附加药物来治疗复方左旋多巴疗效减退、运动功能波动的帕金森病 (PD)患者的临床疗效及安全性。 方法 采用开放、为期 1年的临床研究 ,5 7例患者入组前服用不同剂量的复方左旋多巴制剂 ,培高利特采用剂量滴定法加服 ,临床疗效判断采用改良Webster评定量表 ,PD运动功能评定量表 (MDRSPD)和Hoehn Yahr分级评定进行治疗前后的比较。 结果 改良Webster评定结果显示 ,老年组 14例 (31 8%)有明显进步 ,15例 (34 1%)有进步 ;非老年组分别为 5例 (33 3%)有明显进步和 5例 (33 3%)有进步。PD运动功能量表评定结果显示 :老年组 14例 (31 8%)有明显进步 ,12例 (2 7 3%)有进步 ;非老年组 5例有明显进步 (33 3%)和 6例 (4 0 0 %)有进步。培高利特的平均日服用剂量老年组为 (0 4 0± 0 2 6 )mg ,非老年组为 (0 39± 0 2 0 )mg ,总副反应发生率为 2 3 7%。 结论 培高利特是一种有效的、耐受性良好副作用较小的治疗的附加药物。
Objective To observe the clinical efficacy and safety of pergolide as an additional drug for compound levodopa preparations in the treatment of Parkinson’s disease (PD) patients with compound levodopa dysfunction and fluctuating motor function. Methods A one-year open clinical trial was conducted. Fifty-seven patients were given different doses of compound levodopa before enrollment. Peglitant was supplemented with dose titration. The clinical effect was evaluated by modified Webster scale, PD exercise Functional Rating Scale (MDRSPD) and Hoehn Yahr grading were compared before and after treatment. Results The results of the modified Webster evaluation showed that 14 (31.8%) patients in the elderly group improved significantly and 15 (34.1%) patients improved. In the non-elderly group, 5 patients (33.3%) showed significant improvement and 5 patients (33% 3%) have progressed. Results of PD assessment showed that there were 14 cases (31.8%) in the elderly group and 12 cases (273%) in the elderly group. There were 5 cases in the non-elderly group (33.3%) and 6 cases 40%) have progressed. The average daily dose of pergolide was (0 4 0 ± 0 2 6) mg in the elderly group, (0 39 ± 0 0 0) mg in the non-elderly group, and 23 7% in the total adverse reactions. Conclusion Pergolide is an adjunct to effective, well-tolerated, and less-toxic side effects.